Tuesday, July 26, 2011
Monday, July 25, 2011
Sunday, July 24, 2011
Friday, July 22, 2011
Thursday, July 21, 2011
FDA approves AstraZeneca's anti-clotting drug Brilinta
In continuation of my update on Ticagrelor (Brilinta)......
FDA approves AstraZeneca's anti-clotting drug Brilinta
Wednesday, July 20, 2011
Sunday, July 17, 2011
Tocotrienol could help reduce stroke damage
In continuation of my update on the benefits of Vitamin E
Tocotrienol could help reduce stroke damage
Saturday, July 16, 2011
Grape seed polyphenols may help prevent Alzheimer's disease
In continuation of my update on the usefulness of polyphenols....
Grape polyphenols are also called Vineatrols (see structure : vineatrol / trans-resveratrol)
Tuesday, July 12, 2011
Telaprevir drug shows promise in curing hepatitis C infection
In continuation of my update on Telaprevir...............
Monday, July 11, 2011
Sunday, July 10, 2011
FDA Approves Xarelto (rivaroxaban) to Prevent Deep Vein Thrombosis
We know that, Rivaroxaban (structure below BAY 59-7939) is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceuticals. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects lasts 8–12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible....
Now FDA Approves Xarelto (rivaroxaban) to Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery....
More....
Saturday, July 9, 2011
Sulforaphane-rich foods safe and effective for preventing cancer
In continuation of my update on the benefits of broccoli and sulforaphane............
Labels:
anticancer activity,
broccoli,
sulforaphane
Thursday, July 7, 2011
New drug improves kidney function for patients with type 2 diabetes and chronic kidney disease
We know that Bardoxolone methyl (see the structure, also known as “RTA 402” and “CDDO-methyl ester) is an orally-available first-in-class synthetic triterpenoid belonging to the antioxidant inflammation modulator (AIM) class. It is the most potent known inducer of the Nrf2 pathway to enter clinical development and works to suppress both oxidative stress and inflammation.......
Labels:
Bardoxolone methyl,
diabetes type 2function,
kidney
Wednesday, July 6, 2011
Sunday, July 3, 2011
Saturday, July 2, 2011
New and effective diabetes drug seeking approval
We know that, Dapagliflozin is an experimental drug being studied by Bristol-Myers Squibb in partnership with AstraZeneca as a potential treatment for type 1 and 2 diabetes. Although dapagliflozin's method of action would operate on either type of diabetes or other conditions resulting in hyperglycemia, the current clinical trials specifically exclude participants with Type 1 diabetes.Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2), which is responsible for at least 90% of the glucosereabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.
New and effective diabetes drug seeking approval
New and effective diabetes drug seeking approval
Friday, July 1, 2011
Wednesday, June 29, 2011
Wednesday, June 22, 2011
Tuesday, June 21, 2011
Sunday, June 19, 2011
Thursday, June 16, 2011
Liraglutide as Additional Treatment in Type 1 Diabetes
In continuation of my update on Liraglutide...
Results of a small, observational study conducted at the University at Buffalo suggest that liraglutide (below structure) , an injectable medication used to treat type 2 diabetes, also helps type 1 diabetics on insulin achieve optimal control of their blood glucose levels.
More....
Tuesday, June 14, 2011
New drug more effective than standard treatment to prevent heart-attack deaths
In continuation of my update on ticagrelor .....
Robert Storey, Professor of Cardiology at the University of Sheffield's Department of Cardiovascular Science, presented findings today that confirm one in five deaths in the year following a heart attack could be prevented if a new drug, ticagrelor (see structure), was used instead of the standard treatment, clopidogrel...
More...
Wednesday, June 8, 2011
Positive results from Plexxikon's vemurafenib Phase 2 and 3 trial against metastatic melanoma
We know that, PLX-4032(RG7204, Vemurafenib) is a highly selective inhibitor of BRAF kinase activity, with an IC50 of 44 nmol/L against V600E-mutant BRAF. BRAFV600E cancer-causing mutation occurs in most melanomas and about eight percent of all solid tumors....
More....
Labels:
Anticancer,
BRAF kinase activity,
RG7204,
vemurafenib
Tuesday, June 7, 2011
Formoterol drug improves fat burning and protein metabolism in men
We know that, Formoterol or eformoterol is a long-acting β2-agonist used in the management of asthma and/or chronic obstructive pulmonary disease (COPD). It is marketed in four forms: a dry-powder inhaler (DPI), a metered-dose inhaler (MDI), an oral tablet, and an inhalation solution, under various trade names including Foradil/Foradile (Schering-Plough in the U.S., Novartis rest of world), Oxeze (AstraZeneca), Atock (Astellas), Atimos Modulite (Trinity-Chiesi), and Perforomist (Dey).
Now researchers lead by Dr. Paul Lee of Garvan Institute of Medical Research in Sydney, have for the first time reports that research in animals has shown that formoterol can stimulate the growth of muscle and the burning of fat...
Formoterol drug improves fat burning and protein metabolism in men
Friday, June 3, 2011
Lyxumia®, as an add-on to basal Insulin, shows significant positive phase III results
Sanofi announced today that new results from a Phase III study showed that the investigational product Lyxumia® (lixisenatide see structure above), when used as an add-on therapy to basal insulin (in association with or without metformin), achieved its primary efficacy endpoint of significantly reducing HbA1c versus placebo for patientswith type 2 diabetes without significantly increasing their risk of hypoglycemia...
More...
Wednesday, June 1, 2011
Airtel: Switch off Diesel
Hi ,
I just signed a petition opposing Airtel's use of dirty diesel energy to power their cell phone towers.
Please read the mail below and take action.
Regards,
Dear friends,
Thanks to the telecommunications sector, every new call and SMS is hurting our environment. Lakhs of massive mobile network towers in our country run on dirty diesel.
Airtel is the market leader and trend-setter of the Indian telecom industry. If we get them to switch to renewable energy, it will set an example for the others to follow. Customers are the mainstay of this industry. Airtel would notice if customers ask them to make their calls green by using clean energy to power company’s mobile towers.
You should ask Airtel to switch to renewable energy.
http://www.greenpeace.org/india/en/What-We-Do/Stop-Climate-Change/Green-Electronics/switch-off-diesel/airtel-switch-off-diesel/
Several current and potential Airtel subscribers, asking them to switch to renewable energy will help put pressure on them to act. Since the company is bound to provide good service to its subscribers, they will not be able to ignore this feedback.
Like coal and nuclear, oil too is an unsustainable energy option. The Deepwater Horizon oil spill last year showed the dangers of our addiction to oil.[2] Studies conducted by the Intergovernmental Panel on Climate Change have shown that renewable energy is capable of powering the world.[3] Airtel needs to realise this and quit dirty energy.
Tell them now.
http://www.greenpeace.org/india/en/What-We-Do/Stop-Climate-Change/Green-Electronics/switch-off-diesel/airtel-switch-off-diesel/
Thanks a billion!
Abhishek Pratap
Climate and Energy Campaigner
Greenpeace India
Sources:
1. Dirty Talking? Case for telecom to shift from diesel to renewable, Greenpeace India, May 19, 2011
http://www.greenpeace.org/india/Global/india/docs/cool-it/reports/telecom-report-may-2011.pdf [PDF]
2. BP Oil Spill: How Bad Is Damage to Gulf One Year Later? Time magazine, April 19, 2011
http://news.yahoo.com/s/time/20110419/hl_time/08599206603100
3. Renewable energy can power the world, says landmark IPCC study, Guardian, May 9, 2011
http://www.guardian.co.uk/environment/2011/may/09/ipcc-renewable-energy-power-worlddr.umesh1969@gmail.com
You are receiving this email because someone you know sent it to you from the Greenpeace site. Greenpeace retains no information about individuals contacted through its site, and will not send you further messages without your consent -- although your friends could, of course, send you another message.
New drugs (Victrelis and Incivek ) encouraging for African Americans with hepatitis C
Current standard of treatment of interferon and ribavirun has only been effective in curing 38 to 40 percent of patients with chronic hepatitis C genotype 1. In clinical trials, Victrelis and Incivek, when working in concert with interferon and ribavirun, cured 65 to 75 percent of people with chronic disease and Victrelis-alone doubled the previous cure rate among African Americans......
Victrelis (Boceprevir)
Incivek (Telaprevir)
News Release Archives > New drugs encouraging for African Americans with hepatitis C
Tuesday, May 31, 2011
UCB,s new data for Cimzia® (certolizumab pegol) showed a rapid clinical response across a broad population of RA patients
UCB, announced data which showed that the addition of Cimzia® (certolizumab pegol) to current therapy was associated with a rapid and consistent clinical response in a diverse group of rheumatoid arthritis (RA) patients. Company also claims that, consistent efficacy was observed across patients taking certolizumab pegol whether they had previously received TNF inhibitors or not and whether they received certolizumab pegol monotherapy or with concomitant DMARDs.....
Labels:
Certolizumab pegol,
DMARD,
RA,
rheumatid arthritis
Sunday, May 29, 2011
Saturday, May 28, 2011
Incivek Approved for Hepatitis C
In continuation of my update on telaprevir...
Incivek Approved for Hepatitis C: "MONDAY, May 23 -- Incivek (telaprevir) has been approved by the U.S. Food and Drug Administration for adults with chronic hepatitis C infection who either haven't received standard interferon therapy or haven't responded to it.
Incivek Approved for Hepatitis C: "MONDAY, May 23 -- Incivek (telaprevir) has been approved by the U.S. Food and Drug Administration for adults with chronic hepatitis C infection who either haven't received standard interferon therapy or haven't responded to it.
Friday, May 27, 2011
MAP Pharmaceuticals submits LEVADEX NDA to FDA for treatment of migraine in adults
Levadex is designed to be differentiated from existing migraine treatments. It is a novel formulation of dihydroergotamine (see above structure, DHE), a drug used intravenously in clinical settings to effectively and safely treat migraines.
MAP Pharmaceuticals submits LEVADEX NDA to FDA for treatment of migraine in adultsGout drug success for Novartis
Canakinumab (trade name Ilaris, previously ACZ885) is a human monoclonal antibody targeted at interleukin-1 beta. It has no cross-reactivity with other members of the interleukin-1 family, including interleukin-1 alpha.
We know that, Canakinumab was approved for the treatment of cryopyrin-associated periodic syndromes (CAPS) by the US FDA on June 2009 and by the European Medicines Agency in October 2009. CAPS is a spectrum of autoinflammatory syndromes including familial cold autoinflammatory syndrome, Muckle–Wells syndrome, and neonatal-onset multisystem inflammatory disease.
Canakinumab was being developed by Novartis for the treatment of rheumatoid arthritis but this trial has been discontinued. Canakinumab is also in phase I clinical trials as a possible treatment for chronic obstructive pulmonary disease.
Gout drug success for Novartis
Labels:
ACZ885,
Canakinumab,
Gout,
Ilaris,
rheumatid arthritis
'Turkey tail' mushroom effectively suppresses prostate tumour development
We Know that, Turkey tail/Trametes versicolor — formerly known as Coriolus versicolor and Polyporus versicolor is an extremely common polypore mushroom which can be found throughout the world. Versicolor means 'of several colours' and it is true that this mushroom is found in a wide variety of different colours. T. versicolor is commonly called Turkey Tail because of its resemblance to the tail of the wild turkey. T. versicolor is recognized as a medicinal mushroom in Chinese medicine under the name yun zhi. In China and Japan T. versicolor is used as in immunoadjuvant therapy for cancer. Now Queensland University of Technology (QUT) researchers reported that, the mushroom has the medicinal benefits up to 100 per cent effective in suppressing prostate tumour development in mice during early trials......
'Turkey tail' mushroom effectively suppresses prostate tumour development
Wednesday, May 25, 2011
Linezolid more effective than vancomycin in treating ventilated patients with MRSA pneumonia: Study
In continuation of my update on Linezolid and Vancomycin...
Linezolid more effective than vancomycin in treating ventilated patients with MRSA pneumonia: Study
Linezolid more effective than vancomycin in treating ventilated patients with MRSA pneumonia: Study
Labels:
drug resistant,
linezolid,
MRSA,
Vancomycin
Tuesday, May 24, 2011
Monday, May 23, 2011
Sunday, May 22, 2011
Saturday, May 21, 2011
Friday, May 20, 2011
Thursday, May 19, 2011
Merck receives FDA approval for Victrelis to treat chronic hepatitis C
In continuation of my update on Victrelis (Boceprevir)
Merck receives FDA approval for Victrelis to treat chronic hepatitis C
Merck receives FDA approval for Victrelis to treat chronic hepatitis C
Wednesday, May 18, 2011
New insect repellant may be thousands of times stronger than DEET
In continuation of mosquito repellants and DEET
New insect repellant may be thousands of times stronger than DEET
Ref : http://www.pnas.org/content/early/2011/05/04/1102425108#aff-1
Researchers report the identification and characterization of an Orco family agonist, VUAA1, using the Anopheles gambiae coreceptor (AgOrco) and other orthologues. These studies reveal that the Orco family can form functional ion channels in the absence of an odor-binding OR, and in addition, demonstrate a first-in-class agonist to further research in insect OR signaling. In light of the extraordinary conservation and widespread expression of the Orco family, VUAA1 represents a powerful new family of compounds that can be used to disrupt the destructive behaviors of nuisance insects, agricultural pests, and disease vectors alike...
Ref : http://www.pnas.org/content/early/2011/05/04/1102425108#aff-1
Tuesday, May 17, 2011
Novel two-drug combination cures young patient with extensively drug-resistant tuberculosis
2. http://www.einstein.yu.edu/uploadedFiles/PHD/2010%20Faculty%20Research%20Book.pdf
Labels:
antituberculosis,
clavulanate,
drug resistant,
linezolid,
meropenem
Monday, May 16, 2011
First EffRx NDA accepted for filing by the FDA...
EffRx Pharmaceuticals SA, an Epalinges/Lausanne, Switzerland based drug delivery company announces that the New Drug Application (NDA) for the company's lead development program EX101 has been accepted for filing by the US Food and Drug Administration. EX101 is a proprietary buffered effervescent dosage form of alendronate sodium administered once weekly for treatment of osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis. The EX101 formulation is the first and only effervescent bisphosphonate alternative to tablets. EX101 has a pleasant taste of strawberry and is quickly and completely dissolved.
About Alendronate : Alendronic acid or alendronate sodium ( sold as Fosamax by Merck) is a bisphosphonate drug used for osteoporosis and several other bone diseases. It is marketed alone as well as in combination with vitamin D (2,800 U and 5600 U, under the name Fosamax+D). Merck's U.S. patent on alendronate expired in 2008 and Merck lost a series of appeals to block a generic version of the drug from being certified by the FDA. On February 6, 2008, the US FDA approved the first generic versions of alendronate, which were marketed by Barr Pharmaceuticals and Teva Pharmaceuticals USA. Teva Pharmaceuticals manufactures generic alendronate in 5-milligram, 10-milligram, and 40-milligram daily doses, and in 35-milligram and 70-milligram weekly doses, while Barr made generic alendronate in 70-milligram tablets, which were taken once weekly. Barr pharmaceuticals were subsequently acquired by Teva in July 2008...
Ref : http://www.effrx.com/firsteffrxnda.htm
Sunday, May 15, 2011
Saturday, May 14, 2011
Wednesday, May 11, 2011
Subscribe to:
Posts (Atom)



























